194423-06-8 | CL-387785

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$48.00	$34.00
5mg	95%	in stock	$150.00	$105.00
10mg	95%	in stock	$175.00	$122.00
25mg	95%	in stock	$267.00	$187.00
50mg	95%	in stock	$463.00	$324.00
100mg	95%	in stock	$732.00	$512.00
250mg	95%	in stock	$1,178.00	$824.00

Description

• Catalog Number: AE81319
• Chemical Name: CL-387785
• CAS Number: 194423-06-8
• Molecular Formula: C18H13BrN4O
• Molecular Weight: 381.226
• MDL Number: MFCD02179194
• SMILES: CC#CC(=O)Nc1ccc2c(c1)c(ncn2)Nc1cccc(c1)Br

Computed Properties

• Complexity: 514
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 24
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 3
• XLogP3: 4.3

Literature

• EGFR participates downstream of ERα in estradiol-17β-D-glucuronide-induced impairment of Abcc2 function in isolated rat hepatocyte couplets.

  Archives of toxicology 20160401

• Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.

  International journal of oncology 20120801

• Irreversible protein kinase inhibitors: balancing the benefits and risks.

  Journal of medicinal chemistry 20120726

• 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20120301

• Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.

  Lung cancer (Amsterdam, Netherlands) 20110801

• Epidermal growth factor treatment switches δ-opioid receptor-stimulated extracellular signal-regulated kinases 1 and 2 signaling from an epidermal growth factor to an insulin-like growth factor-1 receptor-dependent mechanism.

  Molecular pharmacology 20110201

• Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.

  Cancer research 20071101

• Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.

  Cancer research 20061201

• Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.

  The Journal of clinical investigation 20061002

• Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

  Journal of medicinal chemistry 20060223

• Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

  PLoS medicine 20051101

• An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

  Cancer research 20050815

• EGFR pharmacogenomics: the story continues to mutate and evolve.

  American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 20050101

• High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.

  Molecular pharmacology 20040601

• 6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity.

  Journal of medicinal chemistry 20010816